Expressing support for the designation of the week of May 4, 2025, through May 10, 2025, as "Tardive Dyskinesia Awareness Week".
This is a House Resolution (H. Res. 396) introduced in the 119th Congress that expresses support for designating a specific week—May 4 to May 10, 2025—as “Tardive Dyskinesia Awareness Week.” The resolution is non-binding and serves to publicly recognize TD and promote awareness among the public and medical community. It notes that TD can result from long-term use of dopamine receptor–blocking medications (such as antipsychotics and antiemetics) and emphasizes the importance of monitoring for TD, as recommended by the American Psychiatric Association. The bill cites an estimated 600,000 people in the U.S. affected by TD, with about 65% undiagnosed, and highlights that treatments approved by the FDA exist to help adults with TD. It concludes by urging Americans to become better informed about TD.
Key Points
- 1The resolution designates May 4–10, 2025, as “Tardive Dyskinesia Awareness Week” and expresses support for this designation.
- 2It highlights that TD is associated with long-term use of dopamine receptor–blocking medications, including antipsychotics and antiemetics, used for certain mental health and gastrointestinal conditions.
- 3It provides a prevalence estimate of about 600,000 people with TD in the United States and notes that roughly 65% of those with TD have not been diagnosed.
- 4It stresses the importance of monitoring TD by health care providers and references regular screening for TD as recommended by the American Psychiatric Association.
- 5It notes that FDA-approved treatments exist for adults with TD and that recognizing and treating TD can positively impact affected individuals; it also urges public awareness.